Home › Funds › DCVC Opportunity Fund II GP, LLC › RXRX
DCVC Opportunity Fund II GP, LLC position in RXRX
RECURSION PHARMACEUTICALCLASS A · Health Care
DCVC Opportunity Fund II GP, LLC reported holding 3,951,141 shares of RXRX (RECURSION PHARMACEUTICALCLASS A) in its Q2 2026 13F filing — a position valued at US$14.5M, representing 84.30% of its reported portfolio and ranking #1 among its reported holdings. DCVC Opportunity Fund II GP, LLC has disclosed RXRX holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How DCVC Opportunity Fund II GP, LLC's RXRX position evolved
DCVC Opportunity Fund II GP, LLC first disclosed a stake in RXRX in Q4 2023 at 3,951,141 shares (US$39.0M). The position peaked in Q1 2024 at 3,951,141 shares, worth US$39.4M. Across 11 filings, DCVC Opportunity Fund II GP, LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 3,951,141 shares valued at US$14.5M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 3.95M | $38.96M | New |
| Q1 2024 | 3.95M | $39.39M | Hold |
| Q2 2024 | 3.95M | $29.63M | Hold |
| Q3 2024 | 3.95M | $26.04M | Hold |
| Q4 2024 | 3.95M | $26.71M | Hold |
| Q1 2025 | 3.95M | $20.90M | Hold |
| Q2 2025 | 3.95M | $19.99M | Hold |
| Q3 2025 | 3.95M | $19.28M | Hold |
| Q4 2025 | 3.95M | $16.16M | Hold |
| Q1 2026 | 3.95M | $12.13M | Hold |
| Q2 2026 | 3.95M | $14.50M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RXRX and 13F data
RXRX (RECURSION PHARMACEUTICALCLASS A) is a Health Care company. 28 other funds we track also report a position in RXRX — the largest reported positions include ARK Invest (US$151.7M), SOFTBANK GROUP CORP. (US$50.0M), MIC Capital Management UK LLP (US$35.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RXRX
- ARK Invest 41.34M sh · $151.71M · Q2 2026
- SOFTBANK GROUP CORP. 13.64M sh · $50.05M · Q2 2026
- MIC Capital Management UK LLP 9.64M sh · $35.39M · Q2 2026
- Data Collective IV GP, LLC 5.94M sh · $21.80M · Q2 2026
More on DCVC Opportunity Fund II GP, LLC
FAQ
How long has DCVC Opportunity Fund II GP, LLC held RXRX?
DCVC Opportunity Fund II GP, LLC has disclosed RXRX holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
What is DCVC Opportunity Fund II GP, LLC's current position in RXRX?
As of Q2 2026, DCVC Opportunity Fund II GP, LLC holds 3.95M shares of RXRX (RECURSION PHARMACEUTICALCLASS A), valued at $14.50M, representing 84.30% of its reported portfolio and ranking #1.
Has DCVC Opportunity Fund II GP, LLC been buying or selling RXRX?
In the latest 13F filing (Q2 2026), DCVC Opportunity Fund II GP, LLC held unchanged its position in RXRX. The position peaked in Q1 2024 at 3.95M shares.
Which other funds hold RXRX?
Other major institutional holders of RXRX include ARK Invest, SOFTBANK GROUP CORP., MIC Capital Management UK LLP, among 28 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.